Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis

Clinical Neurology and Neurosurgery

Volumn 108, Issue 5, 2006, Pages 456-460

  Karrenbauer, Virginija Danylaité ^a   Leoni, Valerio ^b   Lim, Ee Tuan ^c   Giovannoni, Gavin ^c   Ingle, Gordon T ^c   Sastre Garriga, Jaume ^c   Thompson, Alan J ^c   Rashid, Waqar ^c   Davies, Gerard ^c   Miller, David H ^c   Björkhem, Ingemar ^b   Masterman, Thomas ^a  

^a Division of Neurology   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarkers; Magnetic resonance imaging; Multiple sclerosis; Neurodegeneration; Neuroinflammation; Oxysterols

Indexed keywords

24 HYDROXYCHOLESTEROL; CHOLESTEROL DERIVATIVE; GADOLINIUM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN EDEMA; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING;

EID: 33646752106     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2005.07.010     Document Type: Article

References (21)

1. Bagnato F., Jeffries N., Richert N.D., Stone R.D., Ohayon J.M., McFarland H.F., et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 126 (2003) 1782-1789
2. Bielekova B., and Martin R. Development of biomarkers in multiple sclerosis. Brain 127 (2004) 1463-1478
3. Björkhem I., and Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 24 (2004) 806-815
4. Bretillon L., Lütjohann D., Stahle L., Widhe T., Bindl L., Eggertsen G., et al. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J Lipid Res 41 (2000) 840-845
5. Bretillon L., Sidén A., Wahlund L.O., Lütjohann D., Minthon L., Crisby M., et al. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett 293 (2000) 87-90
6. Dzeletovic S., Breuer O., Lund E., and Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem 225 (1995) 73-80
7. Kermode A.G., Tofts P.S., Thompson A.J., MacManus D.G., Rudge P., Kendall B.E., et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 40 (1990) 229-235
8. Lee M.A., Smith S., Palace J., Narayanan S., Silver N., Minicucci L., et al. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?. Brain 122 (1999) 1261-1270
9. Leoni V., Masterman T., Diczfalusy U., De Luca G., Hillert J., and Björkhem I. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci Lett 331 (2002) 163-166
10. Lund E.G., Guileyardo J.M., and Russell D.W. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 96 (1999) 7238-7243
11. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
12. Miller A., Glass-Marmor L., Abraham M., Grossman I., Shapiro S., and Galboiz Y. Bio-markers of disease activity and response to therapy in multiple sclerosis. Clin Neurol Neurosurg 106 (2004) 249-254
13. Miller D.H. MRI monitoring of MS in clinical trials. Clin Neurol Neurosurg 104 (2002) 236-243
14. Miller D.H., Grossman R.I., Reingold S.C., and McFarland H.F. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121 (1998) 3-24
15. Plummer D.L. Dispimage: a display and analysis tool for medical images. Riv Neuroradiol 5 (1992) 489-495
16. Sailer M., O'Riordan J.I., Thompson A.J., Kingsley D.P., MacManus D.G., McDonald W.I., et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 52 (1999) 599-606
17. Schmierer K., Scaravilli F., Altmann D.R., Barker G.J., and Miller D.H. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 56 (2004) 407-415
18. Teunissen C.E., Dijkstra C.D., Polman C.H., Hoogervorst E.L., von Bergmann K., and Lütjohann D. Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neurosci Lett 347 (2003) 159-162
19. Thompson A.J., Montalban X., Barkhof F., Brochet B., Filippi M., Miller D.H., et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47 (2000) 831-835
20. Thompson A.J., Polman C.H., Miller D.H., McDonald W.I., Brochet B., Filippi M., et al. Primary progressive multiple sclerosis. Brain 120 (1997) 1085-1096
21. van Walderveen M.A., Kamphorst W., Scheltens P., van Waesberghe J.H., Ravid R., Valk J., et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 50 (1998) 1282-1288